SDGR vs RLAY
SDGR and RLAY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | SDGRSchrodinger, Inc. | RLAYRelay Therapeutics, Inc. |
|---|---|---|
| Market cap | — | $3.94B |
| P/S | — | 254.5x |
| Revenue | $259.04M(TTM) | — |
| Revenue growth (YoY) | 23.3% | 53.4% |
| Net income | -$54.34M(TTM) | — |
| Earnings growth (YoY) | 44.8% | 18.1% |
| EPS, diluted | $-0.73(TTM) | — |
| EBIT margin | -65.2% | -1971.6% |
| ROE | -31.4% | -31.1% |
| 1y total return | +36.2% | +160.1% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: SDGR frente a RLAY
| Métrica | SDGR | RLAY |
|---|---|---|
| Valor final | $3.5K | $5.1K |
| Retorno total | -65.4% | -48.7% |
| CAGR | -15.5% | -10.1% |
| Volatilidad | 65.8% | 76.4% |
| Sharpe | 0.01 | 0.18 |
| Sortino | 0.01 | 0.28 |
| Caída máxima | -90.2% | -96.8% |
Basado en 1585 días de negociación comunes, 2020-07-16 → 2026-11-04 · tasa libre de riesgo 4.21% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)